Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Study ID
NCT02735239

Study type
Interventional

Study phase
Phase 1/Phase 2

Study status
Active, not recruiting

Trial Acronym

Trial Summary

This is an open-label, Phase 1/2 study to evaluate the safety of durvalumab (MEDI4736) in combination with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced oesophageal cancer (OC) and with neoadjuvant chemo(radio)therapy before surgery in operable OC. The immunotherapy will be given for a 4-week period before starting the standard chemo(radio)therapy, continuing durvalumab treatment once the chemotherapy starts. The study will include 2 phases, a safety run-in Phase 1 (Cohorts A1 and A2) and an expansion Phase 2 (Cohorts B, C, C-FLOT, D).

More informations

Trial Starting Date

Jun 24,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

In order to facilitate the use of our website, we use cookies.